SG10202006863YA - Cl and/or ch1 mutated antibodies for drug conjugation - Google Patents

Cl and/or ch1 mutated antibodies for drug conjugation

Info

Publication number
SG10202006863YA
SG10202006863YA SG10202006863YA SG10202006863YA SG10202006863YA SG 10202006863Y A SG10202006863Y A SG 10202006863YA SG 10202006863Y A SG10202006863Y A SG 10202006863YA SG 10202006863Y A SG10202006863Y A SG 10202006863YA SG 10202006863Y A SG10202006863Y A SG 10202006863YA
Authority
SG
Singapore
Prior art keywords
mutated antibodies
drug conjugation
conjugation
drug
mutated
Prior art date
Application number
SG10202006863YA
Inventor
De La Cuesta Ramon Gomez
Jesús Zurdo
Lars Arne Andreas Arnell
Laurent Ducry
Laurence Bonnafoux
Original Assignee
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201502591A external-priority patent/GB201502591D0/en
Priority claimed from GBGB1504858.0A external-priority patent/GB201504858D0/en
Application filed by Lonza Ag filed Critical Lonza Ag
Publication of SG10202006863YA publication Critical patent/SG10202006863YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
SG10202006863YA 2015-02-16 2016-02-15 Cl and/or ch1 mutated antibodies for drug conjugation SG10202006863YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502591A GB201502591D0 (en) 2015-02-16 2015-02-16 Antibodies
GBGB1504858.0A GB201504858D0 (en) 2015-03-23 2015-03-23 Antibodies

Publications (1)

Publication Number Publication Date
SG10202006863YA true SG10202006863YA (en) 2020-08-28

Family

ID=55359516

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202006863YA SG10202006863YA (en) 2015-02-16 2016-02-15 Cl and/or ch1 mutated antibodies for drug conjugation
SG11201706292SA SG11201706292SA (en) 2015-02-16 2016-02-15 Cl and/or ch1 mutated antibodies for drug conjugation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201706292SA SG11201706292SA (en) 2015-02-16 2016-02-15 Cl and/or ch1 mutated antibodies for drug conjugation

Country Status (7)

Country Link
US (2) US10953106B2 (en)
EP (2) EP3878861A1 (en)
JP (2) JP6932649B2 (en)
KR (1) KR20170116144A (en)
CN (1) CN107207582A (en)
SG (2) SG10202006863YA (en)
WO (1) WO2016131769A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105296433B (en) 2014-08-01 2018-02-09 中山康方生物医药有限公司 A kind of CTLA4 antibody, its medical composition and its use
US10906990B2 (en) * 2015-08-19 2021-02-02 Riken Antibody with non-natural amino acid introduced therein
SG11201811290VA (en) 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN107789630A (en) * 2016-10-08 2018-03-13 四川百利药业有限责任公司 Cysteine engineered antibody toxin conjugate and preparation method thereof
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
CN111909268B (en) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 anti-TNF-alpha humanized monoclonal antibody TCX060 with low immunogenicity and low ADCC/CDC function and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4942643B2 (en) * 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド Partially added antibodies and methods for conjugating them
CN101065151B (en) * 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
PT2845866T (en) * 2006-10-27 2017-08-09 Genentech Inc Antibodies and immunoconjugates and uses therefor
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CA2710779C (en) 2007-12-31 2017-06-20 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf.alpha.
WO2009092011A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
WO2011118739A1 (en) * 2010-03-26 2011-09-29 協和発酵キリン株式会社 Novel antibody having modification site introduced therein, and antibody fragment
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
ES2531471T3 (en) 2011-02-25 2015-03-16 Lonza Ltd Branched linker for protein-drug conjugates
KR102398736B1 (en) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2804631B1 (en) * 2012-01-20 2021-03-17 i2 Pharmaceuticals, Inc. Surrobody conjugates
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
PE20150891A1 (en) 2012-11-07 2015-06-11 Pfizer IL-13 ALPHA 2 ANTI-RECEPTOR ANTIBODIES AND DRUG ANTIBODY CONJUGATES
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
AU2014214751B2 (en) * 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2014179363A1 (en) * 2013-04-29 2014-11-06 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
DK2991683T3 (en) 2013-05-02 2019-11-04 Glykos Finland Oy CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC CHARGE
AR096687A1 (en) * 2013-06-24 2016-01-27 Genentech Inc ANTI-FCRH5 ANTIBODIES
CA2952834A1 (en) * 2014-06-20 2015-12-23 Abgenomics International Inc. Her2 antibody-drug conjugates
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
MA41645A (en) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc SITE-SPECIFIC GENETICALLY ENGINEERED ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
JP2018509933A (en) 2018-04-12
EP3259285A2 (en) 2017-12-27
US20210100914A1 (en) 2021-04-08
SG11201706292SA (en) 2017-09-28
JP7439024B2 (en) 2024-02-27
JP6932649B2 (en) 2021-09-08
KR20170116144A (en) 2017-10-18
WO2016131769A2 (en) 2016-08-25
CN107207582A (en) 2017-09-26
US10953106B2 (en) 2021-03-23
US20180154017A1 (en) 2018-06-07
JP2021175762A (en) 2021-11-04
WO2016131769A3 (en) 2016-12-22
US11833222B2 (en) 2023-12-05
EP3878861A1 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
IL290496A (en) Therapeutic antibodies and their uses
IL265309A (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
IL290457A (en) Antibodies and conjugates thereof
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
IL276695B (en) Antibodies, pharmaceutical compositions and uses thereof
IL247936A0 (en) Anti-egfr antibodies and antibody drug conjugates
IL252015A0 (en) Antibody drug conjugates
IL251938A0 (en) Anti-cs1 antibodies and antibody drug conjugates
IL250189A0 (en) Anti-cdh6 antibody drug conjugates
SG10202002153PA (en) Glycoengineered antibody drug conjugates
HK1255483A1 (en) Antibodies and immunoconjugates
SG10202006863YA (en) Cl and/or ch1 mutated antibodies for drug conjugation
HK1247091A1 (en) Therapeutic antibodies and uses thereof
LU92659B1 (en) Glycooptimized antibody drug conjugates